The invention provides a dosage form and a method of administering an anti-tumor composition comprising tegafur, uracil, and folinic acid to potentiate the coadministration of irinotecan.

Coadministration of 5-fluorouracil/folinic acid in the combination regimen does not change the pharmacokinetics of irinotecan.

The method comprises administering to the subject folinic acid or a pharmaceutically acceptable salt thereof in an amount effective to treat adenosine depletion.

Coadministration of 5-fluorouracil/folinic acid in the combination regimen does not change the pharmacokinetics of irinotecan.

Examples of more bioavailable folate derivatives that may be used include any combination of: folinic acid, tetrahydrofolate, thymidine, 10-formyltetrahydrofolate or methyltetrahydrofolate, or salts thereof.

In Western Washington State, most patients received FOLFOX (oxaliplatin, 5-FU, and leucovorin) chemotherapy.

These positive effects with cycloguanil (a dihydrofolate antagonist) were significantly reduced or abolished with folinic acid supplementation.

These positive effects with cycloguanil, a dihydrofolate reductase inhibitor, were significantly reduced or abolished with folinic acid supplementation.

The most common initial systemic treatment in British Columbia was FOLFIRI (irinotecan, fluorouracil [5-FU], and leucovorin) chemotherapy with bevacizumab (Avastin).

Folic Acid and Antifolates: Vitamin preparations containing folic acid or its derivatives may decrease responses to systemically administered methotrexate.

Calcium folinate tablets, or folinic acid, is an adjuvant manufactured and used in cancer chemotherapy involving the drug methotrexate.

Calcium folinate is a folinic acid which is used to protect normal cells from the toxic effects of methotrexate.

The most commonly used therapeutic regimen, and probably the most effective, is the combination of pyrimethamine with sulfadiazine and folinic acid.

Treatment is given for 1-2 weeks beyond resolution of signs/symptoms; continue leucovorin (folinic acid) 1 week after stopping pyrimethamine.

The most common initial systemic treatment in British Columbia was FOLFIRI (irinotecan, fluorouracil [5-FU], and leucovorin) chemotherapy with bevacizumab (Avastin).